{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000364","form_type":"8-K/A","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.456416+00:00","generated_at":"2026-06-04T20:02:58.255734+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider","bullets":["Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.","Updated net loss: FY2023 $29.7M ($1.12 per share); Q4 2023 $11.7M ($0.44 per share).","Adjustments are non-cash: deferred revenue increased $3.2M, offset by reduction in stockholders' equity.","Cash, equivalents, restricted cash and cash runway unchanged.","Annual Report on Form 10-K for FY2023 filed March 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000364","json":"https://secwatch.observer/filing/0001193805-24-000364.json","markdown":"https://secwatch.observer/filing/0001193805-24-000364.md","text":"https://secwatch.observer/filing/0001193805-24-000364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/e619365_8ka-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:02:58.255734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"378500e39ef76372634ee0bc60ff0ec0324bff02","claim":"Arcturus Therapeutics Holdings Inc. reported fiscal fourth quarter 2023 results: revenue $25.0, net income $11.7 million, EPS $0.44 per share.","evidence_excerpt":"the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter 2023"},{"label":"Revenue","value":"$25.0"},{"label":"Net income","value":"$11.7 million"},{"label":"EPS","value":"$0.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cbc3dac9cfdac178c3a87bf61273282657967108","claim":"Arcturus Therapeutics Holdings Inc. reported fiscal year ended December 31, 2023 results: revenue $157.7 million, net income $29.7 million, EPS $1.12 per share.","evidence_excerpt":"the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$157.7 million"},{"label":"Net income","value":"$29.7 million"},{"label":"EPS","value":"$1.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}